Treatment of Hypertension in Children With Catecholamine-Secreting Tumors: A Systematic Approach

Mauricio Romero1, Gaurav Kapur1, Rossana Baracco1

  • 1Division of Nephrology and Hypertension, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.

Insights

Managing blood pressure in children with catecholamine-secreting tumors (CSTs) requires a specific approach. Sequential alpha-adrenergic blockade, fluid intake, and beta-blockade effectively control blood pressure before surgery for pediatric CSTs.

Area of Science:

  • Pediatric Endocrinology
  • Surgical Oncology
  • Cardiovascular Pharmacology

Background:

  • Pheochromocytoma and catecholamine-secreting tumors (CSTs) present unique challenges in pediatric blood pressure management.
  • Preoperative blood pressure control is critical for surgical safety in children with CSTs.

Purpose of the Study:

  • To evaluate the efficacy of a presurgical management strategy for pediatric patients with CSTs.
  • To assess blood pressure control and perioperative hemodynamic stability in children undergoing treatment for CSTs.

Main Methods:

  • A retrospective review of 10 pediatric patients with CSTs.
  • Sequential alpha-adrenergic blockade (phenoxybenzamine), increased fluid intake, and beta-blockade were used for presurgical management.
  • Continuous infusion of antihypertensive and vasopressor agents was utilized as needed during surgery.

Main Results:

  • Mean duration for blood pressure control was 4.5±2.6 weeks.
  • Eighty percent of patients experienced transient intraoperative hypertension, managed with antihypertensives.
  • Twenty percent required vasopressors for intraoperative or postoperative hypotension (<24 hours).
  • Eighty percent of patients discontinued antihypertensive medications within 4 days post-surgery.

Conclusions:

  • A systematic, multidisciplinary approach using adrenergic blockade is effective for presurgical management of pediatric CSTs.
  • This strategy facilitates effective blood pressure control and hemodynamic stability during the perioperative period.

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
661
Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
2.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
568